Welcome to our dedicated page for Enzo Biochem SEC filings (Ticker: ENZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Enzo Biochem, Inc. (ENZ / ENZB) SEC filings record provides detailed insight into the company’s evolution as a life sciences tools provider and its eventual transition to private ownership. As an SEC registrant, Enzo filed periodic reports and numerous current reports on Form 8-K that document financial performance, strategic shifts, listing status changes, and corporate transactions.
For investors and researchers, Form 8-K filings are central to understanding key events. In 2024 and 2025, Enzo used 8-Ks to report matters such as NYSE notices of non-compliance, the decision to voluntarily delist from the NYSE and move trading to OTCQX, and the later disclosure that its common stock began trading on OTCQX under the symbol ENZB. A June 24, 2025 Form 8-K describes the Agreement and Plan of Merger with Bethpage Parent, Inc. and Bethpage Merger Sub, Inc., including the proposed cash consideration per share and conditions to closing.
An August 19, 2025 Form 8-K records the shareholder vote at a special meeting where the merger proposal was approved. A subsequent August 20, 2025 Form 8-K reports the completion of the merger, stating that Bethpage Merger Sub, Inc. merged with and into Enzo Biochem, Inc., with Enzo surviving as a wholly owned subsidiary of Bethpage Parent, Inc. That filing explains that each share of common stock was converted into the right to receive cash consideration and that the shares ceased trading on OTCQX and other over-the-counter markets.
On the same date, Enzo filed Form 15 (Form 15-12G), certifying the termination of registration of its common stock under Section 12(g) of the Exchange Act and the suspension of its reporting obligations under Sections 13 and 15(d). The Form 15 identifies the common stock, par value $0.01 per share, as the class of securities covered and notes reliance on Rule 12g-4(a)(1) and Rule 12h-3(b)(1)(i). Together, these filings mark Enzo’s transition from a publicly traded, SEC-reporting issuer to a wholly owned private subsidiary.
On Stock Titan’s filings page, users can review these historical 8-Ks and the Form 15 to trace how Enzo’s life sciences business, listing status, and ownership structure changed over time. AI-powered tools can help summarize the implications of each filing, highlight the sections dealing with merger terms, listing changes, and deregistration, and make it easier to understand the regulatory milestones in Enzo Biochem’s corporate history.
Enzo Biochem, Inc. (ENZ) entered into and completed a merger in which Bethpage Merger Sub merged into Enzo, and Enzo became a wholly owned subsidiary of Bethpage Parent.
At the effective time on August 20, 2025, each outstanding share was converted into the right to receive $0.70 in cash per share (subject to withholding). Vested restricted stock units held by directors or vested-but-unsettled RSUs were converted into a cash payment equal to the number of underlying shares multiplied by $0.70. Unvested RSUs and all outstanding options were canceled without consideration. As a result, the reporting persons state they no longer beneficially own any Enzo securities and ceased to own more than 5% of the class.
Enzo Biochem, Inc. filed an S-8 post-effective amendment covering previously filed registration statements for shares issuable under various employee benefit and equity compensation plans. The filing lists multiple prior registration statements dating from 1983 through 2021 that pertain to aggregate share amounts under plans including the 1994 Plan, 1999 Plan, 2011 Incentive Plan, Profit Sharing Plan and inducement awards. The filing is signed by Chief Financial Officer Patricia Eckert.
Enzo Biochem, Inc. filed an S-8 post-effective amendment covering previously filed employee benefit and equity compensation registration statements. The filing lists multiple historical registrations that together authorize issuance under various plans, including registered amounts of 988,951, 950,000, 1,000,000, 2,000,000, 3,000,000, 1,000,000, 2,000,000, 1,000,000, 4,000,000 and an aggregate 960,000 shares tied to inducement awards. The document is a routine update that consolidates past registration statements for employee plans and is signed by Patricia Eckert, Chief Financial Officer.
Enzo Biochem, Inc. filed an S-8 post-effective amendment covering prior employee equity registration statements. The filing lists a series of historic registrations that together cover multiple equity plans, including a 4,000,000-share registration under the 2011 Incentive Plan and a separate 960,000-share registration
Enzo Biochem, Inc. (ENZ) filed an S-8 post-effective amendment that catalogs prior employee equity registration statements covering multiple stock plans. The filing lists historic registrations dating from
Enzo Biochem, Inc. filing confirms classification as a non-accelerated filer and smaller reporting company and lists prior SEC registration statements related to employee benefit and equity compensation plans spanning 1983 through 2021. The filing enumerates multiple registration statement numbers and aggregate share amounts registered under various plans, and is signed by the Chief Financial Officer, Patricia Eckert.
Enzo Biochem, Inc. filed an S-8 post-effective submission that lists prior registration statements covering shares of its common stock issuable under various employee benefit and equity incentive plans. The filing enumerates multiple prior registration statements (1983, 1992, 1994, 1995, 1999, 2002, 2005, 2011, 2014, 2018, 2020, 2021) and specifies aggregate share amounts for several plans. The document is signed by Patricia Eckert, Chief Financial Officer.
FAQ
What is the current stock price of Enzo Biochem (ENZ)?
What is the market cap of Enzo Biochem (ENZ)?
